Covered recipient · General Payments record
JAIME LANDMAN
Allopathic & Osteopathic Physicians Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$185.24
4 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $165.93 | 3 |
| Education | $19.31 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Genentech, Inc. | $139.49 | 1 |
| BioCryst US Sales Co., LLC | $21.16 | 1 |
| Novartis Pharmaceuticals Corporation | $19.31 | 1 |
| Organon LLC | $5.28 | 1 |
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JAIME LANDMAN
NPI 1346204690 · CMS profile ID 105508
Allopathic & Osteopathic Physicians / Allergy & Immunology
AVENTURA, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1346204690?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346204690?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346204690?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1346204690?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
4 matching records · $185.24 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–4 of 4.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| BioCryst US Sales Co., LLC | $21.16 | 12/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222006853 | CMS |
| Genentech, Inc. | $139.49 | 09/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211519823 | CMS |
| Novartis Pharmaceuticals Corporation | $19.31 | 03/19/2025 | Education | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200598757 | CMS |
| Organon LLC | $5.28 | 02/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237696472 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $751,515.35 | 131 |
| PY2024 | Principal investigator | $525,143.48 | 126 |
| PY2023 | Principal investigator | $497,961.58 | 102 |
| PY2022 | Principal investigator | $447,451.34 | 86 |
| PY2021 | Principal investigator | $586,667.15 | 102 |
| PY2020 | Recipient | $11,702.26 | 1 |
| PY2020 | Principal investigator | $473,131.41 | 28 |
| PY2019 | Recipient | $1,525.00 | 1 |
| PY2019 | Principal investigator | $615,806.88 | 59 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
102 records in PY2023
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $558.79 | 12/31/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA CARE | A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 991126597 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $250.00 | 12/22/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127788380 |
| Principal investigator 1 | GENZYME CORPORATION | $375.00 | 12/18/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982505 |
| Principal investigator 1 | GENZYME CORPORATION | $2,960.48 | 12/18/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982517 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $939.60 | 12/13/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1127785645 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $777.60 | 12/06/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127785643 |
| Principal investigator 1 | GENZYME CORPORATION | $282.00 | 12/04/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982485 |
| Principal investigator 1 | GENZYME CORPORATION | $8,857.76 | 12/04/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982497 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,079.54 | 12/01/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines | No dispute reported | 06/30/2026 | 1017200079 |
| Principal investigator 1 | GENZYME CORPORATION | $3,810.00 | 11/20/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982473 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,633.50 | 11/10/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127788382 |
| Principal investigator 1 | GENZYME CORPORATION | $5,543.92 | 11/06/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982453 |
| Principal investigator 1 | GENZYME CORPORATION | $1,329.00 | 11/06/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982465 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $585.00 | 11/01/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127788378 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,972.50 | 10/25/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006238387 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,192.40 | 10/16/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1006235297 |
| Principal investigator 1 | GENZYME CORPORATION | $9,166.56 | 10/10/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982409 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,682.90 | 10/10/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006235859 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $250.00 | 09/18/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006235341 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $939.60 | 09/13/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1006235303 |
| Principal investigator 1 | GENZYME CORPORATION | $5,640.00 | 09/11/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982355 |
| Principal investigator 1 | GENZYME CORPORATION | $7,321.60 | 09/11/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982399 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $431.59 | 09/07/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA CARE | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN | No dispute reported | 06/30/2026 | 1006235833 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,104.20 | 09/06/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006235549 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,633.20 | 09/06/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006238663 |
| Principal investigator 1 | GENZYME CORPORATION | $4,000.00 | 09/05/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982301 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $871.00 | 08/30/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006235853 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $250.00 | 08/29/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006238627 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $390.85 | 08/28/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006235817 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,880.00 | 08/28/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006238621 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $542.80 | 08/17/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006238657 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,034.00 | 08/16/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1006236057 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $250.00 | 08/16/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006236063 |
| Principal investigator 1 | GENZYME CORPORATION | $1,744.00 | 08/14/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982377 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,584.70 | 08/09/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006235845 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,231.00 | 08/04/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006235805 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,641.00 | 08/04/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006235811 |
| Principal investigator 1 | GENZYME CORPORATION | $5,076.00 | 08/02/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982323 |
| Principal investigator 1 | GENZYME CORPORATION | $3,371.52 | 08/02/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982389 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,250.00 | 07/27/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY & ASTHMA | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN | No dispute reported | 06/30/2026 | 1006235839 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $18,856.80 | 07/26/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA CARE | A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 991126507 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,303.60 | 07/19/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1006235827 |
| Principal investigator 1 | GENZYME CORPORATION | $375.00 | 07/17/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982367 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $21,729.70 | 07/14/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA CARE | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 991129573 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,210.20 | 07/12/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006236095 |
| Principal investigator 1 | GENZYME CORPORATION | $7,536.64 | 07/05/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982335 |
| Principal investigator 1 | GENZYME CORPORATION | $4,230.00 | 07/05/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982345 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,040.40 | 07/05/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006236077 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,141.10 | 06/23/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006235555 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $518.00 | 06/16/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1006235309 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,344.00 | 06/16/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006235315 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,544.60 | 06/14/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006235347 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,651.30 | 06/02/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006235591 |
| Principal investigator 1 | GENZYME CORPORATION | $4,512.00 | 05/25/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982249 |
| Principal investigator 1 | GENZYME CORPORATION | $4,917.76 | 05/25/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982259 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,192.40 | 05/17/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1006238383 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $250.00 | 05/12/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006235335 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $179.76 | 05/12/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1006238613 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,266.70 | 05/10/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006238407 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,139.00 | 05/05/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006235353 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,065.40 | 05/03/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006238413 |
| Principal investigator 1 | GENZYME CORPORATION | $3,948.00 | 05/02/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982147 |
| Principal investigator 1 | GENZYME CORPORATION | $10,161.92 | 05/02/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982155 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $179.76 | 04/21/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006238637 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $122.23 | 04/21/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1006238649 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $181.99 | 04/19/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006235579 |
| Principal investigator 1 | GENZYME CORPORATION | $500.00 | 04/17/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982065 |
| Principal investigator 1 | GENZYME CORPORATION | $3,315.00 | 04/17/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982075 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $250.00 | 04/14/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006235561 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,054.00 | 04/14/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006235603 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $173.05 | 04/14/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006238643 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,034.00 | 04/10/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1006235567 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,190.20 | 04/05/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006235597 |
| Principal investigator 1 | GENZYME CORPORATION | $3,441.28 | 04/04/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035982035 |
| Principal investigator 1 | GENZYME CORPORATION | $390.00 | 03/27/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035981227 |
| Principal investigator 1 | GENZYME CORPORATION | $3,666.00 | 03/27/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035981245 |
| Principal investigator 1 | GENZYME CORPORATION | $11,788.80 | 03/27/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035981253 |
| Principal investigator 1 | GENZYME CORPORATION | $296.15 | 03/27/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035981273 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,210.00 | 03/27/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006236071 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,192.40 | 03/15/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1006235585 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,400.00 | 03/08/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006235573 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,845.50 | 03/08/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006238393 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $19,769.40 | 03/03/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006236083 |
| Principal investigator 1 | GENZYME CORPORATION | $2,342.22 | 02/27/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035981177 |
| Principal investigator 1 | GENZYME CORPORATION | $3,666.00 | 02/27/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035981185 |
| Principal investigator 1 | GENZYME CORPORATION | $9,884.16 | 02/27/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035981197 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,072.00 | 02/22/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006238671 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $250.00 | 02/15/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006235321 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,394.00 | 02/15/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1006236089 |
| Principal investigator 1 | GENZYME CORPORATION | $375.00 | 02/13/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035981217 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,366.10 | 02/10/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006235865 |
| Principal investigator 1 | GENZYME CORPORATION | $11,034.88 | 02/06/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035981147 |
| Principal investigator 1 | GENZYME CORPORATION | $600.00 | 02/06/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035981157 |
| Principal investigator 1 | GENZYME CORPORATION | $4,794.00 | 02/06/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035981167 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $76,858.36 | 01/26/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks | No dispute reported | 06/30/2026 | 1017197513 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $14,016.00 | 01/18/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1006235327 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $884.70 | 01/06/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1006238399 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $26,874.21 | 01/05/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous Urticaria Patients Who Completed the Preceding Remibrutinib Phase 3 Studies | No dispute reported | 06/30/2026 | 1017199133 |
| Principal investigator 1 | GENZYME CORPORATION | $6,347.52 | 01/04/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035981109 |
| Principal investigator 1 | GENZYME CORPORATION | $2,865.00 | 01/04/2023 | Non-covered Recipient Entity Florida Center For Allergy Asthma Research | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1035981127 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,083.80 | 01/04/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU | No dispute reported | 06/30/2026 | 1006238631 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $20,705.98 | 01/01/2023 | Non-covered Recipient Entity FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines | No dispute reported | 06/30/2026 | 1017199055 |